Ávila-Pardo SF, Soto-Miranda E, Budar-Fernández LF, Méndez-López MT, Hernández-Maldonado E

Language: Spanish
References: 11
Page: 22-25
PDF size: 199.56 Kb.

ABSTRACT

Induction therapy in renal transplantation is intended to reduce acute rejection. Induction therapy is given with a antilymphocyte-depleting agent or receptor antagonist of interleukin-2 (IL2-RA) before starting, or just at the time immediately after transplantation. Evidence shows benefit in using IL2-RA against placebo in variable immunologic risk patients and different regimens of immunosuppression. There is moderate quality evidence that the use of a antilymphocyte-depleting agent against placebo reduces acute rejection and graft failure in patients with high immunological risk. There is also evidence that in patients with different immunological risk using lymphocyte-depleting agents compared with IL2-RA reduces the incidence of acute rejection but increases the risk of infection and malignancy. From this evidence the use of induction therapy is recommended with a biological agent as part of the initial immunosuppressive therapy in renal transplant recipients and it is recommended that IL2-RA agent is the first line induction therapy.

REFERENCES

1. Webster AC, Playford EG, Higgins G et al. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplantation. 2004; 77: 166-176.

2. Morton RL, Howard K, Webster AC et al. The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrol Dial Transplant. 2009; 24: 2258-2269.

3. Szczech LA, Berlin JA, Aradhye S et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: A meta-analysis. J Am Soc Nephrol. 1997; 8: 1771-1777.

4. Szczech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-lymphocyte antibody induction therapy study group. Ann Intern Med. 1998; 128: 817-826.

5. Thibaudin D, Alamartine E, de Filippis JP et al. Advantage of antithymocyte globulin induction in sensitized kidney recipients: A randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant. 1998; 13: 711-715.

6. Charpentier B, Rostaing L, Berthoux F et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation. 2003; 75: 844-851.

7. Brennan DC, Daller JA, Lake KD et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006; 355: 1967-1977.

8. Webster AC, Ruster LP, McGee R et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev. 2010; 1: CD003897. Doi: 10.1002/14651858.CD003897.pub3.

9. Margreiter R, Klempnauer J, Neuhaus P et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: Results of a prospective randomized trial. Am J Transplant. 2008; 8: 1480-1485.

10. Thomas PG, Woodside KJ, Lappin JA et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation. 2007; 83: 1509-1512.

11. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009; 9 (Suppl 3): S1-155.